Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Cash & Current Investments (2016 - 2025)

Northwest Biotherapeutics' Cash & Current Investments history spans 16 years, with the latest figure at $3.0 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $3.0 million for Q4 2025, up 39.77% from a year ago — trailing twelve months through Dec 2025 was $3.0 million (up 39.77% YoY), and the annual figure for FY2025 was $3.0 million, up 39.77%.
  • Cash & Current Investments for Q4 2025 was $3.0 million at Northwest Biotherapeutics, down from $4.6 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $15.2 million in Q4 2021 to a low of $1.4 million in Q2 2023.
  • The 5-year median for Cash & Current Investments is $4.1 million (2021), against an average of $5.0 million.
  • The sharpest move saw Cash & Current Investments surged 877.49% in 2021, then tumbled 70.52% in 2023.
  • Year by year, Cash & Current Investments stood at $15.2 million in 2021, then plummeted by 54.08% to $7.0 million in 2022, then crashed by 69.48% to $2.1 million in 2023, then rose by 2.3% to $2.2 million in 2024, then surged by 39.77% to $3.0 million in 2025.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $3.0 million, $4.6 million, and $4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.